← Leaderboards
Michele P Calos
Stanford University
$5,346,989
Attributed
$5,346,989
Total exposure
8
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $482.7K · FY2005–07$500K$375K$250K$125K$0
'05
'06
'07
Funding mix
By agency
NIH$5,346,989 · 8
By mechanism
R01$4,061,074 · 4
R21$617,348 · 2
R56$356,101 · 1
R03$312,466 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Peter R Parham$35,417,272
- Mark A Kay$46,920,488
- Thomas None Quertermous$63,279,401
- Nicholas James Leeper$11,709,141
- Bertil E Glader$2,008,258
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyBiotechnologyTechnology /Technique DevelopmentTissue /Cell CultureRecombinaseGene ExpressionGenetically Modified AnimalsTransfection /Expression VectorVirus IntegrationLaboratory MousePlasmidsMolecular Biology Information SystemSite Directed MutagenesisIntegraseMolecular SiteHemophilia BGenetic ScreeningGene Delivery SystemPolymerase Chain ReactionEnzyme StructureNonhuman Therapy EvaluationTransfectionMolecular ShapeAnimal Genetic Material Tag
Grant awards (22)
Transferring Integrase Technology to Animals$356,101
R56 · FY2007 · HL · contact PI
Transferring Integrase Technology to Animals$317,249
R01 · FY2006 · HL · contact PI
Retinal Gene Therapy by Site-Specific Integration$154,416
R03 · FY2006 · EY · contact PI
Transferring Integrase Technology to Animals$324,696
R01 · FY2005 · HL
Retinal Gene Therapy by Site-Specific Integration$158,050
R03 · FY2005 · EY
Transferring Integrase Technology to Animals$324,515
R01 · FY2004 · HL
Extrachromosomal Stable Vectors for Gene Therapy$239,955
R01 · FY2004 · HL
Transferring integrase technology to animals$281,689
R01 · FY2003 · HL
SITE-SPECIFIC INTEGRATION FOR GENE THERAPY$273,700
R01 · FY2003 · DK
Extrachromosomal Stable Vectors for Gene Therapy$239,784
R01 · FY2003 · HL
Custom integration tools for functional genomics$153,580
R21 · FY2003 · HG
Transferring integrase technology to animals$282,349
R01 · FY2002 · HL
SITE-SPECIFIC INTEGRATION FOR GENE THERAPY$273,700
R01 · FY2002 · DK
Extrachromosomal Stable Vectors for Gene Therapy$239,619
R01 · FY2002 · HL
Custom integration tools for functional genomics$153,580
R21 · FY2002 · HG
Transferring integrase technology to animals$279,000
R01 · FY2001 · HL
SITE-SPECIFIC INTEGRATION FOR GENE THERAPY$273,700
R01 · FY2001 · DK
Extrachromosomal Stable Vectors for Gene Therapy$239,460
R01 · FY2001 · HL
Custom integration tools for functional genomics$153,580
R21 · FY2001 · HG
SITE-SPECIFIC INTEGRATION FOR GENE THERAPY$269,259
R01 · FY2000 · DK
CF GENE THERAPY WITH NOVEL NONVIRAL VECTORS$202,399
R01 · FY2000 · DK
RECOMBINASE MEDIATED SITE SPECIFIC INTEGRATION FOR GENE$156,608
R21 · FY2000 · DK